Effector Therapeutics Inc Cash Flow-to-Debt Ratio
Effector Therapeutics Inc cash flow-to-debt ratio. Effector Therapeutics Inc (EFTR) has a Cash Flow-to-Debt Ratio of -0.28x as of March 2024, meaning its operating cash flow of $-7.28 Million could theoretically repay 0% of its total liabilities ($26.30 Million) in one year. Check EFTR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Effector Therapeutics Inc (2019–2023)
Cash flow-to-debt ratio of Effector Therapeutics Inc from 2019 to 2023. Historical debt coverage capacity for Effector Therapeutics Inc across 5 annual periods. Check total reinvestment intensity of Effector Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Effector Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2023)
Effector Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2023. Year-by-year debt coverage analysis for Effector Therapeutics Inc. For the full cash flow conversion analysis, see how efficiently does Effector Therapeutics Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -1.12x | $-29.55 Million | $26.34 Million | ▼ -9.1% |
| 2022 | -1.03x | $-25.90 Million | $25.18 Million | ▼ -52.0% |
| 2021 | -0.68x | $-24.89 Million | $36.77 Million | ▼ -828.7% |
| 2020 | 0.09x | $13.84 Million | $148.95 Million | ▲ +106.4% |
| 2019 | -1.46x | $-27.60 Million | $18.93 Million | — |